All lobbying filings

DESIMONE CONSULTING, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · trade group representing U.S. pharmaceutical research and biotechnology companies

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $30,000.00 income · posted Apr 14, 2026

Official filing document

Bills named in this filing 3

HR 4317
PBM Reform Act of 2025
S 3345
PBM Price Transparency and Accountability Act
HR 7148
Consolidated Appropriations Act, 2026

Lobbying activity 1

Pharmacy

Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform; H.R.4317, PBM Reform Act of 2025; S.3345, PBM Price Transparency and Accountability Act; H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.